Financial Report Insights

bioAffinity Technologies, Inc.(BIAF) earnings

United States · NASDAQ

Latest results · Q2 2026Revenue $1.5M (+19.0%) · EPS $-0.64CyPath Lung is gaining real traction: test volume tripled and the number of ordering practices more than doubled. But each quarter burns about $3.2 million of cash on $1.5 million of revenue, and the company is funding the gap by selling heavily discounted shares and warrants. Two reverse splits in eleven months show how much ownership has been diluted. Higher test volume does not improve the per-share picture unless the company stops needing to raise money.Read the full analysis →

Next earnings reportNov 6, 202610-Q (Q3 2026) · Estimated from past filing datesEarnings calendar

bioAffinity Technologies, Inc. results by period

Period	Revenue	Rev. YoY	Net income	Diluted EPS	Op. margin
Q2 2026	$1.5M	+19.0%	-$3.4M	$-0.64	-220.8%

Figures as reported in each period's filing; YoY compares with the same period a year earlier. Money in the reporting currency.

New to these terms? Revenue vs Net Income: From Sales to Profit · What Is Operating Margin, and Why Do Investors Watch It? · YoY vs QoQ Growth: Which Comparison Should You Use?

Write your own report

bioAffinity Technologies, Inc. earnings analyses

bioAffinity Technologies, Inc. (BIAF) · Q2 2026
Revenue $1.5M (+19.0%) · EPS $-0.64
CyPath Lung tests tripled to 622 and revenue rose 19% to $1.51M, but the operating loss widened 33% to $3.33M, cash was down to $1.0M by early August, and growth is being funded by heavy share dilution and a second reverse split.